RT Journal Article
SR Electronic
T1 Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1515
OP 1520
VO 29
IS 5
A1 ISHIKAWA, TAKASHI
A1 SHIMIZU, SATORU
A1 KATAYAMA, KIYOFUMI
A1 CHISHIMA, TAKASHI
A1 HAMAGUCHI, YOHEI
A1 DOI, TAKAKO
A1 TANABE, MIKIKO
A1 KASAHARA, AKIO
A1 YAMAGUCHI, NAOTAKA
A1 NARUI, KAZUTAKA
A1 OHTA, IKUKO
A1 MATSUMOTO, CHIZURU
A1 SHIMIZU, DAISUKE
A1 KITO, AYAKO
A1 SUDA, TAKASHI
A1 INABA, MASAAKI
A1 ASAGA, TARO
A1 MOMIYAMA, NOBUYOSHI
A1 ICHIKAWA, YASUSHI
A1 YOSHIMOTO, MASATAKA
A1 MORITA, SATOSHI
A1 SHIMADA, HIROSHI
YR 2009
UL http://ar.iiarjournals.org/content/29/5/1515.abstract
AB The feasibility and efficacy of adriamycin or epirubicin in combination with cyclophosphamide followed by weekly paclitaxel (AC/EC-weekly PAC) as adjuvant chemotherapy for breast cancer was investigated. Patients and Methods: Node-positive breast cancer was treated with AC/ EC-weekly PAC, namely AC at 60/600 mg/m2 or EC at 90/600 mg/m2 ×4 at three-week intervals, followed by weekly PAC (80 mg/m2) ×12, namely four cycles of single weekly administration for three weeks followed by a one-week rest (3×4 PAC) or single weekly administration for 12 consecutive weeks (12 PAC). Results: One hundred and three of 109 consecutive patients enrolled were analyzed, of whom 96 (93.2%) completed the regimen. Grade 3/4 neutropenia occurred in 52.4% receiving AC/EC, and 10.9% of 55 receiving 12 PAC but only 2.1% of 48 receiving 3×4 PAC. Neuropathy disorders occurred in more than half receiving PAC, which did not improve after one-week rest in 3×4 PAC. Conclusion: AC/EC-weekly PAC is feasible and without serious complications.